CLB - Core Laboratories N.V.
HOUSTON, Oct. 1, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its third quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
Core Laboratories' 35.1% six-month slide contrasts with stronger Production Enhancement trends and offshore recovery potential amid geopolitical risks.
The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
Strict capital discipline by upstream energy companies is acting as a dampener, making the outlook for the Zacks Oil and Gas-Field Services industry gloomy. FTI, OII and CLB are expected to survive the industry woes.
BlackRock Inc. acquired a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,460,118 shares of the oil and gas company's stock, valued at approximately $86,910,000. BlackRock Inc. owned 16.26% of Core Laboratories
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Advisors Capital Management LLC purchased a new stake in Core Laboratories Inc. (NYSE: CLB) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 237,398 shares of the oil and gas company's stock, valued at approximately $2,766,000. Advisors Capital Management LLC owned 0.52% of Core
On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the firm's stake in Core Laboratories Inc (NYSE: CLB) by 904,557 s
Investors looking for stocks in the Oil and Gas - Field Services sector might want to consider either Drilling Tools International Corp. (DTI) or Core Laboratories (CLB). But which of these two stocks is more attractive to value investors?
Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.
CLB's Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2% from the prior quarter but down 4% from a year earlier, as stronger completion-product sales partly offset disruptions to its service business from conflicts in the Middle East and Russia-Ukraine.
Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript
Core Laboratories (CLB) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.19 per share a year ago.
REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER SHARE OF $0.13; EPS EX-ITEMS OF $0.11, UP 85% SEQUENTIALLY AND DOWN 42% YEAR-OVER-YEAR FREE CASH FLOW OF $ 3.1 MILLION COMPANY REPURCHASED 214,712 SHARES OF COMMON STOCK, FOR $2.7 MILLION AGGREGATE PURCHASE PRICE COMPANY ANNOUNCES Q3 2026 QUARTERLY DIVIDEND HOUSTON, July 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported second quarter 2026 revenue of $124,600,000. Core's operating income was $9,200,000, with earnings per diluted share ("EPS") of $0.13, all in accordance with U.S. generally accepted accounting principles ("GAAP").
The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quarter, falling short of both the Russell 2500 Value Index's +18.50% return and the +20.26% gain posted by the Russell 2500 Index. Live entertainment, media, and technology company, Sphere Entertainment Co. was the top contributor during the quarter on solid earnings and improving operating fundamentals. Shares of Prestige Consumer Healthcare moved lower following disappointing earnings, driven primarily by ongoing supply constraints in its eye care segment and extended lead times in the Middle East.
CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.
HOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.